Part I: Overview of the latest recommendations of the European Germ Cell Cancer Group -- Part II: Special topics about controversial aspects, new results from studies, which might change treatment recommendations and long-term-survivorship: Is there still an indication for radiotherapy in seminoma CS I/ IIA/B?- How should we treat nonseminoma CSI? -- Is there still an indication for diagnostic RPLND in nonseminoma CSI? -- How could the prognosis of patients with intermediate risk disease be improved? -- How should patients with poor-prognosis disease be treated actually? -- How should patients with recurrent disease be treated actually? -- How important are prognostic factors for determining treatment in patients with primary or recurrent disease? -- What should be the boundaries in retroperitoneal residual tumor resection in nonseminoma? -- How should residual disease outside the retroperitoneum be treated? -- What are the recent recommendations for follow up in testicular cancer? -- What are the long-term toxicities to be controlled and treated? -- Consequences of the disease and its treatment concerning sexuality and fertility.